drugset
drugset / Trial / NCT04795479

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

NCT04795479 ↗

Phase 1 Completed 36 enrolled Corcept Therapeutics
RandomizedCrossoverDouble-blindTreatment

Summary

This dedicated T/QT study will investigate the effect of relacorilant on cardiac repolarization in healthy participants.

Timeline

Start
2021-01-22
Primary completion
2021-05-17
Completion
2021-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg Oral
Subject Relacorilant Small molecule 400 mg Oral
Subject Relacorilant Small molecule 800 mg Oral

Indications

No indication recorded.